 | | Vol. 23.27 – 8 August, 2022 |
| |
|
|
| Researchers combined CAR T19 with the FDA-approved BCL-2-inhibitor, venetoclax, and demonstrated in vivo synergy in venetoclax-sensitive non-Hodgkin lymphoma.
[Cancer Discovery] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors showed that pancreas-derived mesenchymal stem cells were capable of regenerating exocrine pancreas when implanted into the kidney capsule of mice with streptozotocin–induced diabetes.
[Science Translational Medicine] |
|
|
|
| Scientists reported a cavity-injectable nanoporter-hydrogel superstructure that created glioma stem cell-specific CAR macrophages/microglia surrounding the cavity to prevent glioblastoma multiforme relapse.
[Science Translational Medicine] |
|
|
|
| Investigators established a saponin+ compound optimally induced system to generate human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes with stable functional attributes in vitro and transplanted in heart failure mice.
[Signal Transduction and Targeted Therapy] |
|
|
|
| The authors performed a Phase I/IIa, single-arm clinical trial to evaluate the safety and efficacy of human umbilical cord-derived MSCs in the treatment of psoriasis and preliminarily explored the possible mechanisms.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Researchers showed that brief hyperthermia induced by focused ultrasound promoted the expression of IFN-γ gene, improving anti-tumor efficacy of ultrasound-responsive bacterium in vitro and in vivo.
[Nature Communications] |
|
|
|
| Systemic CRISPR-Cas9 gene editing using an single guide RNAs (sgRNAs) that targeted human exon 51 efficiently restored dystrophin expression and ameliorated pathologic hallmarks of Duchenne muscular dystrophy, including histopathology and grip strength in a mouse model.
[Molecular Therapy-Nucleic Acids] |
|
|
|
| Wapl deficiency in T cells reduced loop extensions, changed expression of cell cycling genes, reduced proliferation following in vitro and in vivo stimulation, and reduced severity of graft-versus-host disease following experimental allogeneic hematopoietic stem cell transplantation.
[iScience] |
|
|
|
| Scientists reported the successful generation of third-party hematopoietic stem cell (HSC)-engineered human invariant natural killer T (iNKT) cells, using a method combining HSC gene engineering and in vitro HSC differentiation.
[iScience] |
|
|
|
| Researchers reported the therapeutic actions of human adipose-derived MSCs in nephritis, focusing on cellular dynamics and multi-organ networks.
[Communications Biology] |
|
|
|
| Investigators reported the preclinical characterization of Tregs transduced with a human leukocyte antigen (HLA)-A*02 CAR lentiviral vector designated to induce immunosuppression of allograft-specific effector T cells in HLA-A*02-negative recipients of HLA-A*02-positive transplants.
[Gene Therapy] |
|
|
|
| The authors suggested a novel strategy to treat triple negative breast cancer (TNBC) using mesenchymal stem cell-derived extracellular vesicles to transform the behaviors and cellular communication of TNBC cells with other non-cancer cells related to tumorigenesis and metastasis.
[Scientific Reports] |
|
|
|
|
| Scientists assess the benefits and harms of autologous hematopoietic stem cell transplantation for the treatment of systemic sclerosis.
[Cochrane Database of Systematic Reviews] |
|
|
|
| Investigators discuss research progress in developing various genetically engineered carriers. Organic-based nanoparticles including cellulose, collagen, silk-like polymers, elastin-like protein, silk-like elastane, and inorganic-based nanoparticles are discussed in detail.
[Advanced Healthcare Materials] |
|
|
|
| The authors describe the need for next-generation single-cell profiling microtechnologies that allow the direct evaluation and sorting of single cells based on functional properties, with a focus on secreted molecules, which are critical for the in vivo efficacy of current cell therapies.
[Microsystems & Nanoengineering] |
|
|
|
|
| Poseida Therapeutics, Inc. announced it has entered into a broad strategic collaboration and license agreement with Roche, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies.
[Poseida Therapeutics, Inc.] |
|
|
|
| HOOKIPA Pharma, Inc. received US FDA acceptance of its Investigational New Drug application for HB-300, a novel arenaviral immunotherapy for the treatment of metastatic castration-resistant prostate cancer.
[HOOKIPA Pharma, Inc.] |
|
|
|
| STRM.BIO announced it has been awarded a Small Business Innovation Research (SBIR) grant for approximately $2,100,000 from the National Center for Advancing Translational Sciences at the National Institutes of Health.
[STRM.BIO (Cision US, Inc.)] |
|
|
|
|
| October 20 – 21, 2022
Turin, Italy |
|
|
|
|
|
| | University of Illinois at Chicago – Chicago, Illinois, United States |
|
|
|
| | University of Oxford – Oxford, England, United Kingdom |
|
|
|
| | Human Technopole – Milano, Italy |
|
|
|
| | Sanford Research – Sioux Falls, South Dakota, United States |
|
|
|
| | Francis Crick Institute – London, England, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
